NASDAQ:AKBA

Akebia Therapeutics Stock Forecast, Price & News

$3.15

+0.01 (+0.32 %)

(As of 01/20/2021 11:19 AM ET)

Add

Compare

Today's Range

$3.11

Now: $3.15▼

$3.20

50-Day Range

$2.72

MA: $2.99▼

$3.18

52-Week Range

$2.09

Now: $3.15▼

$13.71

Volume101,940 shs

Average Volume5.74 million shs

Market Capitalization$455.30 million

P/E RatioN/A

Dividend YieldN/A

Beta2.11

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. It has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds worldwide. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

MarketRank^™

Overall MarketRank^™

1.78 out of 5 stars

3.3 Analyst's Opinion

Consensus Rating
Akebia Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.29, Akebia Therapeutics has a forecasted upside of 225.5% from its current price of $3.16.
Amount of Analyst Coverage
Akebia Therapeutics has only been the subject of 1 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
Akebia Therapeutics has received 389 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Akebia Therapeutics has received 332 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Akebia Therapeutics has received 53.95% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Akebia Therapeutics and other stocks. Vote “Outperform” if you believe AKBA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AKBA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Akebia Therapeutics does not currently pay a dividend.
Dividend Growth
Akebia Therapeutics does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Akebia Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.55% of the stock of Akebia Therapeutics is held by insiders.
Percentage Held by Institutions
68.98% of the stock of Akebia Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Akebia Therapeutics are expected to grow in the coming year, from ($1.77) to ($0.72) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Akebia Therapeutics is -1.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Akebia Therapeutics is -1.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Akebia Therapeutics has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:AKBA

Previous Symbol

CUSIPN/A

CIK1517022

Webwww.akebia.com

Phone617-871-2098

Employees358

Debt

Debt-to-Equity Ratio0.24

Current Ratio2.15

Quick Ratio1.67

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$335 million

Price / Sales1.36

Cash FlowN/A

Price / Cash FlowN/A

Book Value$3.32 per share

Price / Book0.95

Profitability

EPS (Most Recent Fiscal Year)($1.63)

Net Income$-279,660,000.00

Net Margins-126.86%

Return on Equity-68.51%

Return on Assets-34.01%

Miscellaneous

Outstanding Shares144,539,000

Market Cap$455.30 million

Next Earnings Date3/9/2021 (Estimated)

OptionableOptionable

$3.15

+0.01 (+0.32 %)

(As of 01/20/2021 11:19 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive AKBA News and Ratings via Email

Sign-up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter.

Akebia Therapeutics (NASDAQ:AKBA) Frequently Asked Questions

How has Akebia Therapeutics' stock price been impacted by Coronavirus?

Akebia Therapeutics' stock was trading at $6.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AKBA shares have decreased by 54.0% and is now trading at $3.19.
View which stocks have been most impacted by COVID-19.

Is Akebia Therapeutics a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Akebia Therapeutics stock.
View analyst ratings for Akebia Therapeutics or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Akebia Therapeutics?

Wall Street analysts have given Akebia Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Akebia Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Akebia Therapeutics' next earnings date?

Akebia Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Akebia Therapeutics.

How were Akebia Therapeutics' earnings last quarter?

Akebia Therapeutics, Inc. (NASDAQ:AKBA) released its quarterly earnings results on Tuesday, November, 10th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.17) by $0.25. The biopharmaceutical company earned $59.99 million during the quarter, compared to analysts' expectations of $76.12 million. Akebia Therapeutics had a negative net margin of 126.86% and a negative return on equity of 68.51%.
View Akebia Therapeutics' earnings history.

What price target have analysts set for AKBA?

7 brokerages have issued twelve-month price targets for Akebia Therapeutics' stock. Their forecasts range from $3.00 to $18.00. On average, they anticipate Akebia Therapeutics' share price to reach $10.29 in the next twelve months. This suggests a possible upside of 222.4% from the stock's current price.
View analysts' price targets for Akebia Therapeutics or view Wall Street analyst' top-rated stocks.

Who are some of Akebia Therapeutics' key competitors?

Some companies that are related to Akebia Therapeutics include Ironwood Pharmaceuticals (IRWD), Dicerna Pharmaceuticals (DRNA), Kronos Bio (KRON), Constellation Pharmaceuticals (CNST), Nkarta (NKTX), Aurinia Pharmaceuticals (AUPH), Madrigal Pharmaceuticals (MDGL), uniQure (QURE), Arcturus Therapeutics (ARCT), Olema Pharmaceuticals (OLMA), Heron Therapeutics (HRTX), Endo International (ENDP), DiaMedica Therapeutics (DMCAF), COMPASS Pathways (CMPS) and Supernus Pharmaceuticals (SUPN).
View all of AKBA's competitors.

What other stocks do shareholders of Akebia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer (ET), Micron Technology (MU), TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), NVIDIA (NVDA) and AT&T (T).

Who are Akebia Therapeutics' key executives?

Akebia Therapeutics' management team includes the following people:

Mr. John P. Butler MBA, CEO, Pres & Director (Age 56, Pay $1.02M)
Mr. Michel Dahan, Sr. VP & COO (Age 41, Pay $567.57k)
Ms. Nicole R. Hadas, Sr. VP, Chief Legal Officer & Sec. (Age 47, Pay $497.37k)
Mr. Jason A. Amello, Exec. Officer (Age 52, Pay $578.05k)
Mr. Dell Faulkingham, Sr. VP & Chief Commercial Officer (Age 47, Pay $615.74k)
Mr. David A. Spellman, Sr. VP, CFO & Treasurer (Age 43)
Ms. Kristen K. Sheppard J.D., Esq., VP of Investor Relations
Mr. Douglas Jermasek, VP of Marketing & Strategy
Ms. Tamara Dillon, Sr. VP of HR
Dr. Karen L. Tubridy, Sr. VP & Chief Devel. Officer (Age 58)

What is Akebia Therapeutics' stock symbol?

Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."

How do I buy shares of Akebia Therapeutics?

Shares of AKBA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Akebia Therapeutics' stock price today?

One share of AKBA stock can currently be purchased for approximately $3.19.

How big of a company is Akebia Therapeutics?

Akebia Therapeutics has a market capitalization of $461.08 million and generates $335 million in revenue each year. The biopharmaceutical company earns $-279,660,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. Akebia Therapeutics employs 358 workers across the globe.

What is Akebia Therapeutics' official website?

The official website for Akebia Therapeutics is www.akebia.com.

How can I contact Akebia Therapeutics?

Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-2098 or via email at [email protected]

This page was last updated on 1/20/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here